|
Model Number PCO2015X |
Device Problems
Patient-Device Incompatibility (2682); Mechanics Altered (2984); Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Wound Dehiscence (1154); Bacterial Infection (1735); Purulent Discharge (1812); Emotional Changes (1831); Erythema (1840); Fistula (1862); Hemorrhage/Bleeding (1888); Unspecified Infection (1930); Pain (1994); Swelling (2091); Discharge (2225); Hernia (2240); Discomfort (2330); Injury (2348); Impaired Healing (2378); Blood Loss (2597); Fluid Discharge (2686); No Code Available (3191); Constipation (3274); Unspecified Tissue Injury (4559); Swelling/ Edema (4577)
|
Event Type
Injury
|
Manufacturer Narrative
|
If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of a hernia.It was reported that after a procedure where this device was implanted, the patient experienced chronic pain, infection, open wound; removal surgeries scheduled but cancelled due to diabetes complications.After treatment, the patient experienced cancelled revisions.
|
|
Manufacturer Narrative
|
If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of a left flank hernia.It was reported that after the overlay implant, the patient experienced mental pain, disability, impairment, loss of enjoyment of life, defective mesh, chronic pain, infection, open wound, fistula, draining sinus, positive for (b)(6), redness, swelling, discharge, discomfort, constipation, pouch of pus, blood loss, and recurrence.Post-operative patient treatment included antibiotics and home health care for wound dressings.
|
|
Manufacturer Narrative
|
If information is provided in the future, a supplemental report will be issued.
|
|
Manufacturer Narrative
|
This information was received as a part of an extensive mesh litigation submission to medtronic.The fda was notified of this large complaint receipt.Due to the volume of complaint information received by medtronic, this resulted in a report beyond the 30 day target.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of a left flank hernia.It was reported that after implant, the patient experienced chronic pain, infection, open wound, fistula, and recurrence.Post-operative patient treatment included removal surgeries scheduled but cancelled due to diabetes complications.
|
|
Manufacturer Narrative
|
This information was received as a part of an extensive mesh litigation submission to medtronic.The fda was notified of this large complaint receipt.Due to the volume of complaint information received by medtronic, this resulted in a report beyond the 30 day target.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of a left flank hernia.It was reported that after the overlay implant, the patient experienced chronic pain, infection, open wound, fistula, draining sinus, positive for mssa, redness, swelling, discharge, discomfort, constipation, pouch of pus, blood loss, and recurrence.Post-operative patient treatment included antibiotics and home health care for wound dressings.
|
|
Manufacturer Narrative
|
Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
Event Description
|
The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of a left flank hernia.It was reported that after the overlay implant, the patient experienced mental pain, disability, impairment, loss of enjoyment of life, defective mesh, chronic pain, infection, open wound, fistula, draining sinus, positive for mssa, redness, swelling, discharge, discomfort, constipation, pouch of pus, blood loss, mesh exposure, and recurrence.Post-operative patient treatment included antibiotics and home health care for wound dressings, ct-scan, hernia repair with new mesh.Relevant tests/laboratory data: (b)(6) 2015: abnormal lab of hgba1c: 8.9 (b)(6) 2015: ct abdomen/pelvis showed left lateral wall hernia with fat in the mesentery sac.(b)(6) 2016: consult note referenced a ct that showed a large herniation on left flank with mesh and measured 20x30cm/identified as a sub-costal hernia.(b)(6) 2016: ct abdomen/pelvis showed left lateral wall fat-containing hernia (b)(6) 2016: clinic note stated cultures of draining sinuses were positive for mssa.(b)(6) 2017: history and physical stated an abnormal a1c of 13.7 that had decreased to 11.1.
|
|
Search Alerts/Recalls
|
|
|